2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Sarcoma
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Sarcoma, Ewing
4
Ovarian Neoplasms
4
Breast Neoplasms
4
Neoplasms
3
Insulin-Like Growth Factor I, Resistance To
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Lymphoma
2
Colonic Neoplasms
2
Carcinoid Tumor
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pathologic Complete Response
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
ganitumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled